UBS analyst Michael Leuchten maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of EUR93.00. The company’s shares closed last Friday at $92.88.
Leuchten covers the Healthcare sector, focusing on stocks such as Sanofi, Roche Holding AG, and GlaxoSmithKline. According to TipRanks, Leuchten has an average return of 3.3% and a 62.63% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sanofi with a $114.75 average price target, implying a 23.55% upside from current levels. In a report released today, Deutsche Bank also maintained a Hold rating on the stock with a EUR85.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $113.00 and a one-year low of $72.00. Currently, Sanofi has an average volume of 27.53K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.
Read More on SNYNF:
- Sanofi sees 2023 business EPS up at low single digit rate at CER
- Sanofi reports Q4 business EPS EUR 1.71, up 17.4% at CER
- Sanofi price target raised to EUR 100 from EUR 91 at Berenberg
- Sanofi plans to lay off staff at vaccine factories in India, Reuters says
- Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization
